Thursday, July 30, 2015 6:42:32 PM
By Mike Trout 27 Jul, 2015 News
San Diego – July 27, 2015 – Ansun BioPharma, Inc., a San Diego-based biotech company, is
pleased to announce that an investigation by the United States Attorney’s office over the
misconduct of the former CEO and CFO has been dismissed.“We are pleased with the dismissal of the investigation. With new management in place we have made significant progress with our late stage clinical programs for parainfluenza and influenza,” noted Dr. Ronald Moss, CEO of Ansun Biopharma. “We also have developed a pipeline of therapies against other respiratory viruses such as metapneumovirus and eneterovirus68.” “Ansun had a rough patch with its former CEO and CFO, but it’s a company that has never given up doing important work here in San Diego developing anti-viral therapies for unmet medical needs,” stated Ansun’s general counsel, Mikael Havluciyan. “We were very happy to be able to work with the local U.S. Attorney’s Office to help resolve the investigation in a way that made
sense not just for the Company, but for the national public welfare as well,” explained Mr. Havluciyan.
About Ansun BioPharma
Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of
unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two
products in late stage clinical development. FluDaseTM is a first-in-class broad-spectrum
investigational therapeutic agent to treat all forms of influenza, including pandemic variants
and drug-resistant variants that cannot be treated by any currently approved flu therapies,
including H1N1, H5N1 and H7N9. ParaDaseTM is an investigational nebulized drug which is
designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2
trial for the treatment of lower tract parainfluenza infection in immunocompromised patients.
ParaDaseTM has received Fast Track Designation by the U.S. FDA. For more information, please
visit www.ansunbiopharma.com or www.clinicaltrials.gov using the identifier NCT01644877.
The SwingTrade Portfolio was up 36.2% in 2014, 83.5% in 2013, and 546.6% since inception.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110307454
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM